When might a generic version of Invega Sustenna become available?
The patent expiry for Invega Sustenna (paliperidone palmitate extended-release injectable suspension) is a key factor in the potential availability of generic versions. Information from DrugPatentWatch.com indicates that the principal patent for Invega Sustenna is set to expire in 2027 [1]. However, the exact date for generic availability can be influenced by various factors, including the success of any patent challenges or exclusivities that might extend beyond the listed patent expiry.
What are the implications of Invega Sustenna's patent expiry?
Once patents expire and any associated exclusivities lapse, the market can open to generic manufacturers. This typically leads to increased competition, which can result in lower drug prices for patients and healthcare systems. For Invega Sustenna, this means that after its patent protections end, other pharmaceutical companies may be able to produce and market their own versions of paliperidone palmitate extended-release injectable suspension.
Who manufactures Invega Sustenna and what is their role in generic availability?
Invega Sustenna is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [2]. As the originator company, Janssen holds the patents and exclusivities for the drug. Their involvement in patent litigation or defense efforts can significantly impact the timeline for generic entry.
Are there any ongoing legal challenges affecting Invega Sustenna's patent status?
Information regarding specific ongoing legal challenges to Invega Sustenna's patents is not readily available in the provided context. However, patent litigation is common in the pharmaceutical industry and can delay or accelerate the availability of generics. DrugPatentWatch.com is a resource that tracks such patent landscapes and any associated legal proceedings [1].
What is paliperidone palmitate and how does Invega Sustenna work?
Paliperidone palmitate is the active ingredient in Invega Sustenna. It is a long-acting injectable antipsychotic used to treat schizophrenia and schizoaffective disorder [2]. The "palmitate" form of paliperidone is a prodrug that is slowly released into the body, providing a sustained therapeutic effect over time. Invega Sustenna is administered as an intramuscular injection, with dosing schedules typically ranging from once every two weeks to once every three months, depending on the formulation [2].
What are the alternatives to Invega Sustenna for treating schizophrenia?
Beyond generic versions of paliperidone palmitate, there are other treatment options for schizophrenia and schizoaffective disorder. These include other long-acting injectable antipsychotics with different active ingredients, as well as oral antipsychotic medications. The choice of treatment depends on individual patient needs, physician recommendations, and treatment history.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.janssen.com/